The company's innovative approach focuses on using allogeneic innate cell therapy, mass-produced from stem cells, to destroy all types of solid tumors. LIfT Biosciences aims to overcome the commercial and medical barriers of current therapies by creating a scalable and patented product that can safely and consistently eliminate tumors that other treatments cannot. Their initial focus is on rare tumors such as NSCLC, liver, ST sarcoma, and pancreatic cancer. They are currently seeking partners for clinical trials and commercialization.